[
  {
    "id": "12-asthma-mx-2-ocr-complete--1--chunk-0",
    "bookId": "12-asthma-mx-2-ocr-complete--1-",
    "sectionTitle": "OBESITY & ASTHMA",
    "content": "<!-- Page 1 -->\n\n# OBESITY & ASTHMA\n9908269710\nPremium resident group\nNon Type 2\n\nmechanical effect is postulated to be the result of decreased tidal volume and decreased functional residual capacity in obesity\n\nproinflammatory cytokines can be induced or produced by adipocytes.\n\ngenetic susceptibilities, events during fetal development, comorbidities such as GERD, pollution, common dietary and microbiome alterations\n\nT2 immune system in maintains visceral tissue homeostasis and suggest that medications that inhibit T2 inflammation (such as corticosteroids or new anti-T2 biologic agents) might lead to increases in obesity and metabolic dysfunction\n\nDR. BHARATH KATHI MD DNB FIP FACI EDARM\n59\n\n---\n\n<!-- Page 2 -->\n\n# MECHANISM\n\nObesity →\n*   Low-grade inflammation ①\n*   Insulin resistance ②\n*   Mechanical effects ③\n*   Dysanapsis ④\n*   Impaired airway host defense\n\nThese factors lead to:\n*   Metabolic dysfunction\n    *   Cardiovascular disease\n    *   Neurovascular disease\n    *   Renal failure\n    *   Cancer\n*   Asthma\n\n---\nDR BHARATH KATHI MD DNB FIP FADI EDAM\n\n---\n\n<!-- Page 3 -->\n\n# ASTHMA OBESITY\n\n**Table 61.1 Factors Contributing to Increased Asthma Severity in Obese Patients**\n\n1.  Altered physiology (e.g., decreased functional residual capacity, dysanapsis)\n2.  Lower baseline lung function\n3.  Increased risk of infection\n4.  Altered response to infection\n5.  Impaired response to medications\n6.  Comorbidities\n\n**Table 61.2 Comorbidities That May Contribute to Asthma Severity in Obese Patients**\n\n*   Gastroesophageal reflux\n*   Obstructive sleep apnea\n*   Depression\n*   Nasal polyposis\n\n---\n\n<!-- Page 4 -->\n\n* Standard asthma medications\\* \\*\n* Treatment of comorbidities \\*\n* Dietary intervention ✓\n* Lifestyle weight loss interventions (including exercise)\n* Bariatric surgery\n\nDR BHARATH KATHI MD, DNB, FIP, FACE, EDABM\n\n---\n\n<!-- Page 5 -->\n\n# Steroid resistant asthma\n\na failure to respond to a high dose of oral prednisone/prednisolone (40 mg once daily over 2 weeks), ideally with a 2-week run-in with matched placebo.\n\n---\n\n<!-- Page 6 -->\n\nBRONCHIAL\nASTHMA\n\n---\n\n<!-- Page 7 -->\n\nClassification & STEP WISE THERAPY of Stable asthma GINA 2023\n\n*   Controller medications: ↓ Inflammation ⇒ ICS, Anti leukotriene\n*   Reliever medications: as-needed relief for acute symptoms. → fast & long acting\n*   Preferred reliever / Rescue Rx: low dose ICS- formoterol (better bronchoprotection & ↓ exacerbation rates) > SABA\n    *   SABA → fastest acting & short acting\n    *   E.D. ICS - FORMETROL\n\n**SABA ALONE**\nINFLAMMATION NOT TARGETED\n\n**ICS - FORMETROL**\nTARGETS BOTH INFLAMMATION & BRONCHOSPASM\n\n---\n\n<!-- Page 8 -->\n\n## GINA UPDATE\n\n### GINA EMPHASISES ON Personalized asthma management:\nAssess, Adjust, Review for individual patient needs\n\n### ASTHMA TREATMENT TRACKS FOR ADULTS (India)\n\n**ASSESS**\n*   Confirmation of diagnosis if necessary\n*   Symptom control & modifiable risk factors (see Box 2-2B)\n*   Comorbidities\n*   Inhaler technique & adherence\n*   Patient preferences and goals\n\n**ADJUST**\n*   Treatment of modifiable risk factors and comorbidities\n*   Non-pharmacological strategies\n*   Asthma medications (adjust down/up/between tracks)\n*   Education & skills training\n\n---\n\n**TRACK 1 (Most preferred and recommended)**\n*   Reliever: LDICS + Formoterol\n    *   *Anti Inflammatory Reliever [AIR]*\n\n**TRACK 2 (Only if Track 1 not possible or is not preferred by a patient).**\n*   Reliever: SABA\n    *   (SABA-ICS)\n\n---\nDr. Bharath kathi MD FIP\n\n---\n\n<!-- Page 9 -->\n\n# Step wise management - TRACK 1 ~LDICS formoterol\n\n## MART [3-5]\nMaintenance And Reliever Therapy",
    "wordCount": 538,
    "index": 0,
    "subTopicId": "1766794361642-9wqnjvqdn"
  },
  {
    "id": "12-asthma-mx-2-ocr-complete--1--chunk-1",
    "bookId": "12-asthma-mx-2-ocr-complete--1-",
    "sectionTitle": "| Infrequent symptoms",
    "content": "| Infrequent symptoms                               | Frequent symptoms ≈ Daily",
    "wordCount": 8,
    "index": 1,
    "subTopicId": "1766794361642-9wqnjvqdn"
  },
  {
    "id": "12-asthma-mx-2-ocr-complete--1--chunk-2",
    "bookId": "12-asthma-mx-2-ocr-complete--1-",
    "sectionTitle": "---",
    "content": "---\n\n<!-- Page 10 -->\n\nBRONCHODILATORS\n\nAnti inflammatory agents\n*   ICS\n*   Leukotriene antagonists\n*   Mast cell stabilizers\n*   MAB\n\n**Diagram Labels:**\n*   A\n*   B Normal Airway\n*   C During Asthma Symptoms\n*   Airways\n*   Lungs\n\n---\n\n<!-- Page 11 -->\n\nBRONCHODILATORS\n\n* ✓\nβ2 AGONIST\n*\n\nM3 BLOCKER\n*\n\nMETHYL\nXANTHANES\n\n---\n\n<!-- Page 12 -->",
    "wordCount": 58,
    "index": 2,
    "subTopicId": "1766794361642-9wqnjvqdn"
  },
  {
    "id": "12-asthma-mx-2-ocr-complete--1--chunk-3",
    "bookId": "12-asthma-mx-2-ocr-complete--1-",
    "sectionTitle": "β2",
    "content": "# β2\n\n**LEVALBUTEROL (S- enantiomer)**\n*   Most selective\n*   Most potent SABA\n\n**Salbutamol/ALBUTEROL**\n**Terbutaline**\n*   SABA (<4hrs)\n*   Acute asthma\n\n**MOA**\n*   Activate β2-adrenergic receptors → ↑intracellular cyclic AMP, → relaxation of airway smooth muscle cells → bronchodilation\n\n**Diagram:**\nATP\nAC → B AGONIST → CAMP ↑\n\n*   **Non bronchodilator effects:**\n    *   inhibition of mast cell mediator release,\n    *   inhibition of sensory nerve activation, and\n    *   reduction in plasma exudation.\n\n**ICS-β2**\n*   Steroids increases responsiveness of beta receptor\n\n---\n\n<!-- Page 13 -->\n\n*   **LABA (>24hrs)**\n    *   Indacaterol, Olodaterol, Vilanterol (fast)\n    *   Abediterol (slow acting)\n*   **LABA (>12hrs)**\n    *   Salmeterol (slow acting)\n    *   Formoterol (fast)\n*   **SABA (<4Hrs)**\n    *   Salbutamol, Terbutaline\n\n---\n\n**$\\beta_2$ agonist**\n**Bronchodilators**\nRx: Hypokalemia\n*   Tremor (M/C)\n*   Palpitation\n*   \\* stimulate $\\beta_2$ adrenoreceptors on muscle spindles $\\rightarrow$ physiological tremor \\*\n*   Hypokalemia: shift of extracellular potassium into the intracellular space.\n\n---\n\nWith prolonged exposure to a drug, downregulation of the $\\beta$-receptor may occur, limiting therapeutic efficacy (i.e., tachyphylaxis).\n\n---\n\n<!-- Page 14 -->\n\n\n\n# Salbutamol vs Formoterol vs Salmeterol\n\n*   Formoterol moderately lipophilic can stimulate the receptor directly, also a significant fraction enters the cell membrane in the form of a **depot**, from where it leaches out gradually to interact with the receptor $\\rightarrow$ longer duration\n*   Salmeterol highly lipophilic is taken up into the cell membrane & approaches the receptor by slow lateral diffusion through the membrane $\\rightarrow$ slower action\n*   Once at the receptor, the long side-chain of salmeterol also binds to an **secondary binding site (exosite)** $\\rightarrow$ allows salmeterol to contact the $\\beta$2 receptor repeatedly while the drug remains anchored allowing for an **extended duration of action**.\n\n| | Salbutamol | Formoterol | Salmeterol |\n|---|---|---|---|\n| Potency | moderately potent | very potent | potent |\n| Onset of action | rapid | rapid | delayed > 10 min |\n| Duration of action | 4-6 h | > 12 h | > 12 h |\n| Mechanism of action | direct | membrane depot | exosite |\n| Clinical role | rescue/acute use | rescue and maintenance | maintenance |\n\n*   Most preferred : Formoterol It is a selective long-acting $\\beta$2-agonist\n*   200-fold greater activity at $\\beta$2-receptors compared to $\\beta$1-receptors\n*   It has a quick onset and long duration of action\n\n---\n\n<!-- Page 15 -->\n\n8 x 5 x 2.5 ml\nRx\nLevosalbutamol and Ipratropium\nBromide Respirator Solution\nduolin\n\nLEVOSALBUTAMOL:\n50 mcg inhaler\n1.25mg respule\n\nduolin\ninhaler\nwith\ndose counter\nEach actuation delivers\nIpratropium Bromide IP\nequivalent to Ipratropium\nBromide Anhydrous .. 20 mcg\nLevosalbutamol Tartrate\nequivalent to\nLevosalbutamol .......... 50 mcg\nSuspended in\nPropellant HFA 134a ........ q.s.\n\nComposition:\nEach 2.5 ml pulmule contains\nIpratropium Bromide IP equivalent to\nIpratropium Bromide (anhydrous) .......... 500 mcg\nLevosalbutamol Sulphate IP equivalent to\nLevosalbutamol ................................. 1.25 mg\nin an isotonic solution.\nq.s.\n\nCipia\nLevosalbutamol\nInhaler 50 mcg\nlevolin\n\n---\n\n<!-- Page 16 -->\n\nniveoli\ninhaler\ndose counter\n\nEach actuation delivers:\nFormoterol Fumarate ... 6 mcg\n(As Formoterol Fumarate Dihydrate IP)\nBeclomethasone\nDipropionate IP ... 100 mcg\nSuspended in Propellant\nHFA1340 ... q.s.\nAlso contains absolute\nalcohol IP ... 17.7 %v/v\n\nEach actuation delivers:\nVilantrol Trifenatate\neq. to Vilantrol ... 12.5 mcg\nFluticasone Furoate Ph. Eur. ... 100 mcg\nSuspended in inert propellant\nStore protected from moisture,\nat a temperature not exceeding 30°C.\nDosage and Indications:\nAs directed by the Physician\n\nmaxiflo 125\nsynchrobreathe\ndose counter\n\nEach actuation delivers:\nFluticasone\nPropionate IP ... 125 mcg\nFormoterol Fumarate\nDihydrate IP ... 6 mcg\nPropellant HFA 134a ... q.s.\n\nseroflo\ninhaler 125\nwith\ndose counter\n\nEach actuation delivers:\nSalmeterol ... 25 mcg\n(as Salmeterol Xinafoate IP)\nFluticasone Propionate IP ... 125 mcg\nSuspended in\npropellant HFA 1340 ... q.s.\n\nforacort 400\nsynchrobreathe\nwith\ndose counter\n\nEach actuation delivers:\nFormoterol Fumarate ... 6 mcg\n(As Formoterol Fumarate Dihydrate IP)\nBudesonide IP ... 400 mcg\nSuspended in\nPropellant HFA-227ea ... q.s.\n\nFORMOTEROL 6mcg per puff\n20 MCG per respule\nSalmeterol: 25 mcg per puff\nVilantrol : 12.5 mcg per puff\nIndacetrol 110 mcg\n\n---\n\n<!-- Page 17 -->\n\nSAMA\nIpratropium bromide\nTiotropium bromide\nLAMA\n\nM3- Bronchospasm\nM3 antagonist - bronchodilatation \\*\n(COPD)\n\nUmeclidinium bromide\nGlycopyrronium bromide\n\n- β₂ adrenergic receptor\n- M₃ muscarinic receptor\n\nX β blockers X\nβ₂ Agonists\n\nAnticholinergics\n\nCOPD\n\nADRS: dry mouth; in elderly patients, glaucoma and urinary retention \\* \\*\n\n---\n\n<!-- Page 18 -->\n\n\n\n# Glycopyrronium versus Tiotropium\n\n**Glycopyrronium**\n*   Fast acting, Less S/E, More m3 selectivity\n*   Low oral bioavailability; lesser systemic side-effects¹\n*   Higher selectivity^ for M3:M2 receptors (10.7 vs 4.3)²\n\n**Tiotropium**\n*   Rapid onset of action (6.1 min vs 29.4 min)*²\n*   Faster dissociation from M2 receptors²\n\n---\n¹ International Journal of COPD 2012;7:729-741.\n² J Pharmacol Exp Ther 2012;343:520-528\n\n*Small text at bottom left (partially visible):*\nVolume of inhaled doses inhaled and systemic exposure\nLesser selectivity ratio\n\n---\n\n<!-- Page 19 -->\n\n6 x 5 x 2.5 m\n-> SAGA\nLevosalbutamol and Ipratropium\nBromide Respiratory Solution SAMA\nduolin\n\nIpratropium: 20 mcg\nper puff\n500mcg respule\n\nComposition\nEach 2.5 ml pulmule contains\nIpratropium Bromide IP equivalent to\nIpratropium Bromide (anhydrous) ................. 500 mcg\nLevosalbutamol Sulphate IP equivalent to\nLevosalbutamol ........................................ 1.25 mg\nIn an isotonic solution.\nq.s.\n\nduolin\ninhaler\nwith\ndose counter\nEach actuation delivers\nIpratropium Bromide IP\nequivalent to Ipratropium\nBromide Anhydrous - 20 mcg\nLevosalbutamol Tartrate\nequivalent to\nLevosalbutamol ................. 50 mcg\nSuspended in\nPropellant HFA 134a ............ q.s.\nCipla\n\nLevosalbutamol\nInhaler 50 mcg\nlevolin\nCipla\n\n---\n\n<!-- Page 20 -->\n\n\n\n# (Steroid)*\n\n\n\n## Inhalational:\n*   Beclomethasone ✓\n*   Budesonide * ✓\n*   Fluticasone * ✓\n*   Ciclesonide ✓\n\n\n\n## Anti inflammatory => Inhibition of Phospholipase A2\nCell Membrane Phospholipids\n*   Phospholipase A2 (crossed out) ✓\n    *   Arachidonic Acid\n        *   Lipoxygenase → LTs (Leukotrienes)\n        *   Cyclooxygenase\n\n\n\n### S/E ICS (Side Effects Inhaled Corticosteroids)\n1.  Oral Candidiasis\n2.  Hoarseness of voice\n\n\n\n## Several molecular mechanisms\n*   ↓Eosinophils, activated T lymphocytes, and surface mast cells → ↓ airway hyperresponsiveness *\n*   Inhibition of transcription factors NF-κB → which switch off transcription of multiple activated genes encoding _inflammatory proteins_\n*   Switch off inflammatory genes in asthma through a combination of a **direct inhibition of HAT activity** (histone acetyltransferase) and by the **recruitment of HDAC2**\n*   CS increase the expression of β2-receptors, which may contribute to the **complementary clinical effects observed when CS are combined with LABA**\n\n---\n\n<!-- Page 21 -->\n\n**Asthma** ⇌ Fluticasone vs **Budesonide** (**COPD**) → ↓ Pneumonia\n\nFluticasone propionate is a **fluorinated glucocorticoid** which facilitates almost complete first-pass metabolism to an inactive metabolite.\nIt is **highly lipophilic** which increases **potency** of fluticasone : longest **half-life of 10 hrs**, which allows for twice daily dosing.\nThe **potency** of fluticasone is **twice that of beclomethasone and budesonide**\nVery low water solubility of ICS (eg fluticasone) prolongs the **intraluminal dissolution time** of the ICS and can extend their *local anti-inflammatory* **efficacy**.\nHowever, such increased **pulmonary residence time** may also enhance the duration of the **local immunosuppressive action** of ICS in the airways/ lung. ? ↑ pneumonia in COPD?\n\nTamm M et al. Respir Med 2012;106(S1):S9-S19\n\n---\n\n<!-- Page 22 -->\n\n\n\n### Niveoli Inhaler\n\n*   **niveoli** inhaler\n*   with **dose counter**\n*   Each actuation delivers:\n    *   Formoterol Fumarate ... 6 mcg (As Formoterol Fumarate Dihydrate IP)\n    *   Beclomethasone Dipropionate IP ... 100 mcg\n    *   Suspended in Propellant HFA134a ... q.s.\n    *   Also contains absolute alcohol IP ... 17.7 %v/v\n\n\n\n### Budesonide Nebules Suspension\n\n*   **Budesonide Nebules Suspension BP**\n*   0.5 mg/2 ml\n*   Budesonide 0.5 mg/2 ml\n*   Budesonide 1 mg/2 ml\n*   Budesonide 2 mg/2 ml\n*   *Logos/Watermarks: Cipla, PharmEasy*\n\n\n\n### Maxiflo Inhaler\n\n*   **maxiflo** synchroBreathe **125**\n*   with **dose counter**\n*   Each actuation delivers:\n    *   Fluticasone Propionate IP ... 125 mcg\n    *   Formoterol Fumarate Dihydrate IP ... 6 mcg\n    *   Propellant HFA 134a ... q.s.\n\n\n\n### Seroflo Inhaler\n\n*   **seroflo** inhaler **125**\n*   with **dose counter**\n*   Each actuation delivers:\n    *   Salmeterol ... 25 mcg (as Salmeterol Xinafoate IP)\n    *   Fluticasone Propionate IP... 125 mcg\n    *   Suspended in propellant HFA 134a ... q.s.\n\n\n\n### Foracort Inhaler\n\n*   **foracort** synchroBreathe **400**\n*   with **dose counter**\n*   Each actuation delivers:\n    *   Formoterol Fumarate ... 6 mcg [As Formoterol Fumarate Dihydrate IP]\n    *   Budesonide IP ... 400 mcg\n    *   Suspended in Propellant HFA-227ea ... q.s.",
    "wordCount": 1363,
    "index": 3,
    "subTopicId": "1766794361642-3zu4553ec"
  },
  {
    "id": "12-asthma-mx-2-ocr-complete--1--chunk-4",
    "bookId": "12-asthma-mx-2-ocr-complete--1-",
    "sectionTitle": "Dosage Information (Blue Box)",
    "content": "### Dosage Information (Blue Box)\n\n*   Budesonide **200mcg** per puff\n*   **0.5 to 1 mg per respule**\n*   Beclomethasone 100 mcg\n*   Fluticasone **125mcg** per puff\n\n---\n\n<!-- Page 23 -->\n\nMETHYL XANTHANES-\nTheophylline, Aminophylline\n\n*   `X` `X`\n*   `↑ S|E`\n*   ✓ Inhibition of phospho diesterases- increases cyclic AMP\n*   `X` Blocks adenosine receptor\n*   CALCIUM RELEASE FROM SARCOPLASMIC RETICULUM\n*   Anti inflammatory- by activating histone deacetylase-2 (HDAC 2)\n\n---\n\n<!-- Page 24 -->\n\n| SIDE EFFECT           | PROPOSED MECHANISM                               |\n| :-------------------- | :----------------------------------------------- |\n| Nausea and vomiting   | PDE4 inhibition                                  |\n| Headaches             | PDE4 inhibition                                  |\n| Gastric discomfort    | PDE4 inhibition                                  |\n| Diuresis              | A₁ receptor antagonism                           |\n| Epileptic seizures    | A₁ receptor antagonism                           |\n| Cardiac arrhythmias   | PDE3 inhibition, A₁ receptor antagonism          |\n\nRx\n1. Seizures\n2. Arrythmias\n\n---\n\n<!-- Page 25 -->\n\n\n\n# LEUKOTRIENE ANTAGONISTS\n\nARACHIDONIC ACID\n↓ LOX\n(Lox⊖)\n5-Lipooxygenase\n↓\nLT\n**Zileuton- HEPATITIS**\n(Handwritten: \\*\\*)\n\n(Handwritten: AnHleukotnu)\n\nZafirlukast\nMontelukast\nPranlukast\n(Handwritten: Black box warning)\n\nLT Receptor blocker\n\nCysteinyl-leukotriene receptor type 1 antagonists inhibit the smooth muscle bronchoconstriction, microvascular leakage, and eosinophilic airway inflammation\n\n---\n\n<u>Headache, Eosinophilia, Vasculitis</u>\n<u>Neuropsychitric manifestations (depression, suicidal thoughts)</u> ✔️\n\n---\n\nCHRUG STRAUSS SYNDROME ?? \\*\n(Handwritten: Neuropsychiatric Symptoms)\n\n---\n\n<!-- Page 26 -->\n\n\n\n# Mast cell stabilizers\n\nMast cell sensitization\n\nExposure to antigen\n\nMAST CELL\nMAST CELL\nMAST CELL\n\nAnti inflammatory drugs\nPreventive drugs\n\\*Exercise induced asthma\n\\*Food allergy\n\nMast cell degranulation\n\n\\* Cromoglycate, Nedocromil, Ketotifen. \\*\n\n---\n\n<!-- Page 27 -->\n\n\n\n## STEP 1-2\n*As needed LDICS - formoterol* *200mcg* *6mcg*\n*GINA 2023*\n\nThe usual dose of as-needed budesonide-formoterol In Steps 1–2 Is one Inhalation of _200/6 mcg_ dry powder Inhaler (delivered dose _160/4.5 mcg_) taken _whenever needed_ for symptom relief, or before exercise If needed. The maximum recommended dose In a single day Is a total of _72 mcg formoterol_ (54 mcg\n*72mcg*\n\n\n\n## STEP 3\n*Daily BD + SOS*\n\nThe usual dose of budesonide-formoterol _200/6 mcg_ dry powder Inhaler (delivered dose _160/4.5 mcg_,\n1 Inhalation _twice daily_ plus 1 Inhalation _as needed_ for symptom relief. See Box 12 (_p.52_) for more Information about dosage, Including the _maximum number of Inhalations_ In any day.\n\n*\nThe maintenance dose of MART can be Increased by _doubling the number of maintenance Inhalations_. However, the rellever should still be _low-dose ICS-formoterol_.\n\n---\n\n<!-- Page 28 -->\n\nAdd-on azithromycin (500mg three times a week for 6 months) can be considered after specialist referral for adult patients with persistent symptomatic asthma despite high dose ICS-LABA. [ Severe Asthma: Non Type2 ]\nThe evidence for this recommendation includes a meta-analysis of two clinical trials that found reduced asthma exacerbations\n\nGeneral principles of stepping down asthma treatment (GINA 2023)\n\n*   Consider stepping down when asthma symptoms have been well controlled and lung function has been stable for 3 or more months (Evidence D). If the patient has risk factors for exacerbations (Box 2-2, p 38), for example a history of exacerbations in the past year, 318 or persistent airflow limitation, step down only with close supervision.\n*   \\* Choose an appropriate time (no respiratory infection, patient not travelling, not pregnant). \\*\n*   Step down through available formulations to reduce the ICS dose by 25-50% at Intervals of 2-3 months (see Box 3-7 in full 2023 GINA report for details of how to step down different treatments).\n\n---\n\n<!-- Page 29 -->\n\n| Inhaled corticosteroid                               | Total daily ICS dose (mcg) |           |       |\n| :----------------------------------------------------- | :------------------------- | :-------- | :---- |\n|                                                        | Low                        | Medium    | High  |\n| Budesonide (DPI, or pMDI, standard particle, HFA)      | 200-400                    | >400-800  | >800  |\n| Fluticasone propionate (DPI)                           | 100-250                    | >250-500  | >500  |\n| Fluticasone propionate (pMDI, standard particle, HFA) | 100-250                    | >250-500  | >500  |\n\n20mcg LD\nBudesonide > 800mcg\nFluticane > 500mcg\n\n---\n\n<!-- Page 30 -->\n\nMost important is patient education\n\nMakeAGIF.com\nAATH KATH\n\n---\n\n<!-- Page 31 -->",
    "wordCount": 658,
    "index": 4,
    "subTopicId": "1766794361642-9wqnjvqdn"
  },
  {
    "id": "12-asthma-mx-2-ocr-complete--1--chunk-5",
    "bookId": "12-asthma-mx-2-ocr-complete--1-",
    "sectionTitle": "UNCONTROLLED ASTHMA",
    "content": "# UNCONTROLLED ASTHMA\n\nUncontrolled asthma includes one or both of the following:\n*   Poor symptom control (frequent symptoms or reliever use, activity limited by asthma, night waking due to asthma)\n*   Frequent exacerbations ($\\ge$2/year) requiring oral corticosteroids (OCS), or serious exacerbations ($\\ge$1/year) requiring hospitalization\n\n_Handwritten note:_ Poor symptom control + frequent exacerbations",
    "wordCount": 52,
    "index": 5,
    "subTopicId": "1766794361642-9wqnjvqdn"
  },
  {
    "id": "12-asthma-mx-2-ocr-complete--1--chunk-6",
    "bookId": "12-asthma-mx-2-ocr-complete--1-",
    "sectionTitle": "| Difficult-to-treat asthma",
    "content": "| Difficult-to-treat asthma",
    "wordCount": 3,
    "index": 6,
    "subTopicId": "1766794361642-9wqnjvqdn"
  },
  {
    "id": "12-asthma-mx-2-ocr-complete--1--chunk-7",
    "bookId": "12-asthma-mx-2-ocr-complete--1-",
    "sectionTitle": "---",
    "content": "---\n\n<!-- Page 32 -->",
    "wordCount": 5,
    "index": 7,
    "subTopicId": "1766794361642-9wqnjvqdn"
  },
  {
    "id": "12-asthma-mx-2-ocr-complete--1--chunk-8",
    "bookId": "12-asthma-mx-2-ocr-complete--1-",
    "sectionTitle": "Difficult-to-treat asthma",
    "content": "# Difficult-to-treat asthma\n\\* HDICS - LABA\n+ OCS\n\n*   Difficult-to-treat asthma that is uncontrolled despite prescribing of medium or high dose inhaled corticosteroids (ICS) with a second controller (usually LABA) or with maintenance OCS.\n*   It does not mean a (difficult patient).\n*   In many cases, asthma may appear to be difficult-to-treat because of modifiable factors such as incorrect inhaler technique, poor adherence, smoking or comorbidities, or because the diagnosis is incorrect.\n\n---\n\n<!-- Page 33 -->\n\n*   **Severe asthma**\n    *   Mild\n        *   Step 1-2\n    *   Moderate\n        *   Step 3-4\n    *   Severe\n        *   Step 4\n        *   HDICS - LABA\n\n*   It is a subset of difficult-to-treat asthma.\n    *   asthma that is uncontrolled despite adherence with maximal optimized high dose ICS- LABA (OR)\n    *   Treatment with systemic steroids for 50% of previous year to prevent it from becoming uncontrolled.\n    *   and treatment of contributory factors, or that worsens when high dose treatment is decreased.\n*   Also sometimes called 'severe refractory asthma'. However, with the advent of biologic therapies, the word 'refractory' is no longer appropriate.\n*   Asthma is not classified as severe if it markedly improves when contributory factors such as inhaler technique and adherence are addressed.\n\n---\n\n<!-- Page 34 -->\n\n\n\n# BASELINE ASSESSMENT FOR BIOLOGICS\n\n*   CONFIRM PRESENCE OF SEVERE ASTHMA (using HDICS + LABA)\n*   WORK UP FOR T2 INFLAMMATION (BLOOD EOSINOPHILS, FENO)\n*   SERUM PERIOSTIN: In asthma, periostin is recognized as a biomarker of type 2 inflammation; POSTN gene expression is up-regulated in bronchial epithelial cells by IL-13 and IL-4.\n\n(Handwritten diagram interpretation):\nS.IgG $\\leftarrow$ Eosinophils $\\uparrow$ (IL-4, IL-5, IL-13) $\\leftarrow$ TH2 $\\rightarrow$ AHR, $\\uparrow$ NO\nTH2 and ILC2 (IL-5, IL-13) both lead to T2 inflammation.\nT2 inflammation can be NonType2, possibly Neutrophilic.\n\n---\n\n<!-- Page 35 -->\n\n\n\n# SEVERE ASTHMA\n\n\n\n## Potential Rx\n\n\n\n### Anti TSLP\n*   *(Handwritten notes related to TSLP pathway/targets, often associated with T2 inflammation):*\n    *   IL4, IL5, IL13\n    *   Leads to Eosinophila\n    *   IgE X\n    *   IgE X\n    *   ILC2, IL5, IL13\n    *   Allergo\n\n---\n\n*(From SEVERE ASTHMA, classification into two main types:)*\n\n\n\n## T2 HIGH ASTHMA\n*   *(Handwritten characteristics of T2 HIGH):*\n    *   ↑ IgE\n    *   [IL4, IL5, IL13]\n    *   ↑ IgE\n\n\n\n### Subtypes of T2 HIGH Asthma:\n\n#### 1. ALLERGIC ASTHMA with EOSINOPHILIA\n*   **Recommended Rx:**\n    *   Anti IgE \\*\n    *   Anti IL5 \\*\n    *   Anti IL4 \\*\n\n#### 2. NON ALLERGIC EOSINOPHILIC ASTHMA\n*   **Recommended Rx:**\n    *   X (No specific treatment indicated or not applicable)\n    *   Anti IL5 ✓\n    *   Anti IL4 ??\n*   *(Handwritten note below box):* X IL5 X\n\n#### 3. ALLERGIC ASTHMA\n*   **Recommended Rx:**\n    *   Anti IgE\n    *   Anti IL4\n\n---\n\n\n\n## NON T2 ASTHMA\n*   *(Handwritten characteristics/mechanisms of NON T2):*\n    *   X IL4 IL5 X (IL4 and IL5 are not involved)\n    *   X IL13 X (IL13 is not involved)\n    *   Airway epithelium (or Alarmin-producing epithelium)\n    *   ~ (Alarmins) TSLP (Suggests alarmins from the epithelium, including TSLP, might be involved)\n\n*   **Recommended Rx:**\n    *   Macrolide\n    *   Bronchial Thermoplasty\n    *   ? Anti TSLP (Question mark suggests it's a potential or investigational treatment)\n\n---\n\n<!-- Page 36 -->\n\nT2 targets\n*   IL-5\n    *   Mepolizumab ✓\n    *   Reslizumab ✓\n    *   IL-5Rα\n        *   Benralizumab \\*\n*   IgE\n    *   Omalizumab\n*   IL-4\n    *   IL-4Rα\n        *   IL-4\n        *   IL-13\n            *   Dupilumab\n\nAllergy => Anti IgE\n~~Anti IL4~~\n\nEosinophil => Anti IL5\nAnti IL4\n[IL4 + IL13]\n\nNon Type 2\n=> ? Anti TSLP\n\n---\n\n<!-- Page 37 -->\n\n**OMALIZUMAB** (Mc) (Allergic) Asthma\n\n*   Binds to circulating free IgE, thereby preventing IgE binding to its receptor (FcεR1) expressed on the surface of basophils and mast cells (6-12 month)\n*   Dose: 75-375 mg SC per IU every 2-4 weeks based on age, weight and IgE levels\n*   Indicated for severe allergic asthma\n\n> What factors may predict good asthma response to anti-IgE? ✔️\n> *   Blood eosinophils ≥260/µl ++ (FeNO ≥20 ppb)\n> *   Allergen-driven symptoms ++ Childhood-onset asthma +\n\n---\n\n<!-- Page 38 -->\n\n*   **ILS PATH**\n    *   Anti IL5: Mepo\n    *   Anti IL5R: Benra\n\n*   **ILS**: *eosinophil maturation, survival* and transition of this granulocyte from the bone marrow into the *systemic circulation*\n*   Approved for use in patients with *severe eosinophilic asthma* that demonstrate a blood eosinophil count of *≥300 cells/mL* and experience *frequent exacerbations*. They reduce the risk of exacerbations by *40% to 50%* with modest effects on lung function\n*   MEPOLIZUMAB (EGPA): *100 mg SC every 4 weeks* (300 mg SC every 4 weeks for)\n*   Benralizumab: *30 mg SC every 4 weeks for the first 3 doses then every 8 weeks*\n\n---\n\n**What factors may predict good asthma response to anti-ILS/5R?**\n*   ✓ Higher blood eosinophils +++\n*   ✓ More exacerbations in previous year +++\n*   ✓ *Adult-onset of asthma* +\n*   ✓ *Nasal polyposis* ++\n\n---\n\n<!-- Page 39 -->\n\n\n\n# IL4 PATH\n\n*   **α-unit of IL-4 receptor blockade** → **blockage of T2-cytokines, IL-4, and IL-13.**\n*   **IL4 & IL13** → **recruitment of eosinophils, B cell class switch to IgE** production, goblet cell hyperplasia and mucus production, airway remodeling & airway epithelial cell expression of iNOS => **FeNO**\n*   **Approved in severe eosinophilic asthma with exacerbations in the past year with either blood eosinophil count of ≥150 cells/mL or a FeNO > 25 ppb** \\* **Anti-IL4R may also be used to treat • Moderate/severe atopic dermatitis** \\*\n*   Nasal polyposis\n*   DOSE: **200 mg or 300 mg SC every 2 weeks after initial loading dose (400-600mg)**\n\n---\n\nWhat factors may predict good asthma response to anti-IL4R?\n*   **Higher blood eosinophils +++ • Higher FeNO +++**\n\n---\n\n<!-- Page 40 -->\n\n**Anti tslp**\n**Tezepelumab**\n\nAdd-on anti-TSLP for severe asthma\n\n**Regulatory approvals may include:** For ages ≥12 years: tezepelumab (anti-TSLP) 210 mg by SC injection every 4 weeks. Self-administration may be an option. Check local regulatory and payer criteria, as they may differ from these.\n\n**Mechanism:** tezepelumab binds circulating TSLP, a bronchial epithelial cell-derived alarmin implicated in multiple downstream processes involved in asthma pathophysiology.\n\n**Eligibility criteria** (in addition to criteria for severe asthma): these vary between payers, but usually include\n* Severe exacerbations in the last year\n\n*Anti-TSLP may also be considered in patients with no elevated T2 markers (section 7.1)*\n\n---\n\n<!-- Page 41 -->\n\n\n\n# Severe asthma: Treatment targets & biomarkers\n\n\n\n## Axes\n*   **Y-axis (left):** Blood eosinophils µL⁻¹ (Threshold: 300)\n    *   *Handwritten note:* Eosinophils\n*   **X-axis (bottom):** Serum total IgE kU·L⁻¹ (Threshold: 30)\n*   **Y-axis (right):** Sputum eosinophils % (Threshold: 3)\n\n\n\n## Quadrants\n\n\n\n### Top-left: Nonatopic asthma\n*   Anti-IL-5 and other anti-Th2 (A)\n*   Omalizumab (POC) (C)\n*   *Handwritten note:* Anti IL4\n\n\n\n### Top-right: Atopic asthma with eosinophilia\n*   Omalizumab (A)\n*   Anti-IL-5 and other anti-Th2 (A)\n*   *Handwritten note:* ↑IgE ↑Eosno, Anti IL4\n\n\n\n### Bottom-left: Th2-low asthma\n*   Bronchial thermoplasty (B) (crossed out)\n*   Macrolides (C)\n*   Weight loss (B)\n*   ? ANHTSLCP\n*   *Handwritten note:* IgE low Eosin low\n\n\n\n### Bottom-right: Atopic asthma\n*   Omalizumab (A)\n*   *Handwritten note:* ↑IgG\n\n---\n*Ersidure et al. Eur Respir J 47(1):304-316, 2016*\n\n---",
    "wordCount": 1157,
    "index": 8,
    "subTopicId": "1766794361642-9wqnjvqdn"
  }
]